Fig. 1From: Recent advances in therapeutic strategies for triple-negative breast cancerClassification and therapeutic options for TNBC. ADC: antibody‒drug conjugates; AR: androgen receptor; LAR: luminal androgen receptor; M: mesenchymal; MSL: mesenchymal-stem-like; PARP: poly-adenosine diphosphate ribose polymerase; PI3K: phosphoinositol-3 kinase; TKI: tyrosine kinase inhibitor; and TNBC: triple-negative breast cancerBack to article page